The Potential of Candesartan to Retard the Progression of Aortic Stenosis

Update Il y a 4 ans
Reference: NCT00699452

Woman and Man

  • | Country :
  • Finland
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The present study defines a blinded, randomized, placebo-controlled, prospective study, the aim of which is to determine the influence of effective treatment with Type 1 angiotensin II (Ang II) receptor (AT-1R) antagonist, using candesartan (target dose 16 mg) on stenotic aortic valves. The investigators will specifically quantify whether candesartan attenuates the key pathogenic mechanisms of aortic valve stenosis, namely inflammation, fibrosis, elastin degradation, calcification, and neovascularization.


Inclusion criteria

  • Aortic Valve Stenosis

Links